Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 6.16
SRPT's Cash to Debt is ranked lower than
63% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 56.57 vs. SRPT: 6.16 )
Ranked among companies with meaningful Cash to Debt only.
SRPT' s Cash to Debt Range Over the Past 10 Years
Min: 4.29  Med: 10000.00 Max: No Debt
Current: 6.16
Equity to Asset 0.70
SRPT's Equity to Asset is ranked higher than
51% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SRPT: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
SRPT' s Equity to Asset Range Over the Past 10 Years
Min: -0.09  Med: 0.89 Max: 0.98
Current: 0.7
-0.09
0.98
F-Score: 1
Z-Score: -1.25
M-Score: -1.30
WACC vs ROIC
8.01%
-627.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -17400.16
SRPT's Operating margin (%) is ranked lower than
94% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.21 vs. SRPT: -17400.16 )
Ranked among companies with meaningful Operating margin (%) only.
SRPT' s Operating margin (%) Range Over the Past 10 Years
Min: -28680.87  Med: -215.28 Max: -71.16
Current: -17400.16
-28680.87
-71.16
Net-margin (%) -17417.48
SRPT's Net-margin (%) is ranked lower than
94% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. SRPT: -17417.48 )
Ranked among companies with meaningful Net-margin (%) only.
SRPT' s Net-margin (%) Range Over the Past 10 Years
Min: -27020  Med: -286.12 Max: -4.93
Current: -17417.48
-27020
-4.93
ROE (%) -133.29
SRPT's ROE (%) is ranked lower than
87% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -31.69 vs. SRPT: -133.29 )
Ranked among companies with meaningful ROE (%) only.
SRPT' s ROE (%) Range Over the Past 10 Years
Min: -309.2  Med: -92.63 Max: -16.44
Current: -133.29
-309.2
-16.44
ROA (%) -95.19
SRPT's ROA (%) is ranked lower than
88% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -26.89 vs. SRPT: -95.19 )
Ranked among companies with meaningful ROA (%) only.
SRPT' s ROA (%) Range Over the Past 10 Years
Min: -93.53  Med: -62.30 Max: -4.62
Current: -95.19
-93.53
-4.62
ROC (Joel Greenblatt) (%) -584.01
SRPT's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. SRPT: -584.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SRPT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -978.9  Med: -575.45 Max: -309.3
Current: -584.01
-978.9
-309.3
Revenue Growth (3Y)(%) -73.30
SRPT's Revenue Growth (3Y)(%) is ranked lower than
90% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SRPT: -73.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SRPT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.3  Med: 9.10 Max: 343.4
Current: -73.3
-73.3
343.4
EBITDA Growth (3Y)(%) 62.10
SRPT's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. SRPT: 62.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SRPT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.3  Med: 2.50 Max: 62.1
Current: 62.1
-36.3
62.1
EPS Growth (3Y)(%) 0.40
SRPT's EPS Growth (3Y)(%) is ranked higher than
57% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. SRPT: 0.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SRPT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.7  Med: -0.20 Max: 216.5
Current: 0.4
-62.7
216.5
» SRPT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SRPT Guru Trades in Q2 2015

Columbia Wanger 3,532,677 sh (+7.95%)
Steven Cohen 174,900 sh (unchged)
Jim Simons 295,178 sh (-25.56%)
Steven Cohen 936,600 sh (-44.98%)
» More
Q3 2015

SRPT Guru Trades in Q3 2015

Paul Tudor Jones 24,042 sh (New)
Jim Simons 507,738 sh (+72.01%)
Steven Cohen 910,370 sh (-2.80%)
Columbia Wanger 2,133,684 sh (-39.60%)
» More
Q4 2015

SRPT Guru Trades in Q4 2015

Steven Cohen 2,375,700 sh (+160.96%)
Steven Cohen 380,200 sh (unchged)
Paul Tudor Jones Sold Out
Columbia Wanger 1,164,690 sh (-45.41%)
Jim Simons 188,578 sh (-62.86%)
» More
Q1 2016

SRPT Guru Trades in Q1 2016

Steven Cohen 2,962,231 sh (+24.69%)
Jim Simons Sold Out
Columbia Wanger 1,119,893 sh (-3.85%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:SHSE:600645, SHSE:600161, SHSE:603566, BOM:532523, NAS:NKTR, SZSE:300347 » details
Traded in other countries:AB3A.Germany,
Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.

Top Ranked Articles about Sarepta Therapeutics Inc

Sarepta Shares Tumble Following FDA Committee's Decision Panel does not recommend approval of muscular dystrophy treatment drug
On the news that a Food and Drug Administration advisory committee had declined to recommend the approval of eteplirsen, an experimental drug designed to treat Duchenne muscular dystrophy (DMD), the price of shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell by nearly half in early trading Tuesday. Read more...

Ratios

vs
industry
vs
history
P/B 6.98
SRPT's P/B is ranked lower than
76% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 3.51 vs. SRPT: 6.98 )
Ranked among companies with meaningful P/B only.
SRPT' s P/B Range Over the Past 10 Years
Min: 2  Med: 5.07 Max: 238.78
Current: 6.98
2
238.78
P/S 706.33
SRPT's P/S is ranked lower than
95% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. SRPT: 706.33 )
Ranked among companies with meaningful P/S only.
SRPT' s P/S Range Over the Past 10 Years
Min: 1.55  Med: 25.07 Max: 39930
Current: 706.33
1.55
39930
Current Ratio 2.91
SRPT's Current Ratio is ranked lower than
65% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. SRPT: 2.91 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s Current Ratio Range Over the Past 10 Years
Min: 0.76  Med: 7.50 Max: 36.25
Current: 2.91
0.76
36.25
Quick Ratio 2.91
SRPT's Quick Ratio is ranked lower than
62% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. SRPT: 2.91 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 7.50 Max: 36.25
Current: 2.91
0.76
36.25
Days Sales Outstanding 1.00
SRPT's Days Sales Outstanding is ranked higher than
98% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. SRPT: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.22  Med: 87.87 Max: 1158.5
Current: 1
28.22
1158.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.66
SRPT's Price/Net Cash is ranked lower than
81% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. SRPT: 17.66 )
Ranked among companies with meaningful Price/Net Cash only.
SRPT' s Price/Net Cash Range Over the Past 10 Years
Min: 3.03  Med: 6.54 Max: 72.6
Current: 17.66
3.03
72.6
Price/Net Current Asset Value 11.21
SRPT's Price/Net Current Asset Value is ranked lower than
74% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 5.18 vs. SRPT: 11.21 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SRPT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.95  Med: 6.28 Max: 42
Current: 11.21
2.95
42
Price/Tangible Book 7.33
SRPT's Price/Tangible Book is ranked lower than
70% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. SRPT: 7.33 )
Ranked among companies with meaningful Price/Tangible Book only.
SRPT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.41  Med: 4.96 Max: 395
Current: 7.33
2.41
395
Price/Median PS Value 28.25
SRPT's Price/Median PS Value is ranked lower than
98% of the 679 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. SRPT: 28.25 )
Ranked among companies with meaningful Price/Median PS Value only.
SRPT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.08  Med: 3.78 Max: 1605.5
Current: 28.25
0.08
1605.5
Earnings Yield (Greenblatt) (%) -25.30
SRPT's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: -9.20 vs. SRPT: -25.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SRPT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -65.93  Med: 0.00 Max: 82
Current: -25.3
-65.93
82

More Statistics

Revenue (TTM) (Mil) $1.25
EPS (TTM) $ -5.01
Beta0.84
Short Percentage of Float53.45%
52-Week Range $8.00 - 41.97
Shares Outstanding (Mil)45.77

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2 41
EPS ($) -3.98 -3.58 -3.44
EPS without NRI ($) -3.98 -3.58 -3.44
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for SRPT

Headlines

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Is the FDA’s decision to delay Sarepta drug decision good or bad? Nobody really knows May 27 2016
Delayed FDA Decision Sends Sarepta Therapeutics Soaring May 27 2016
Sarepta: What the Bulls Say May 26 2016
Sarepta: We've Seen This Before May 26 2016
Trending Now: SRPT May 26 2016
[$$] Muscular Dystrophy Day at the FDA May 25 2016
[$$] Business Watch May 25 2016
[$$] Muscular Dystrophy Day at the FDA May 25 2016
Trade school: how to take advantage of weekly options May 25 2016
Sarepta shares soar on FDA's eteplirsen review delay May 25 2016
[$$] Sarepta Jumps on FDA Delay but Remains a Buy May 25 2016
[$$] Sarepta: FDA's Decision on Dystrophy Drug Delayed May 25 2016
Sarepta Gets Second Wind, As FDA Delays Drug Decision — Again May 25 2016
Sarepta (SRPT) Stock Spikes After FDA Delayed Approval Decision May 25 2016
[$$] How Options Investors Can Profit From Sarepta May 25 2016
Here's How to Trade 7 of the Market's Most-Active Stocks Right Now May 25 2016
Sarepta Therapeutics: Is This Why the FDA Delayed Its Decision? May 25 2016
Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today? May 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)